Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients - AIRCo study

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-007748-33-NL

Enrollment

Registered

2008-12-11

Start date

2010-04-09

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin resistance in colon cancer patients MedDRA version: 9.1 Level: LLT Classification code 10022489 Term: Insulin resistance

Interventions

Trade Name: Dipeptiven Product Name: Dipeptiven Product Code: RVG19489 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: Dipeptiven Other descriptive name: Alanyl-Glutam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Colon cancer patients scheduled for elective abdominal surgery. 18 to 75 yrs. Capable of giving informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Diabetes Mellitus Thyroid medication Anti-hypertensive medication Corticosteroids Diuretics

Design outcomes

Primary

Measure	Time frame
Main Objective: The effect of the dipeptide alanyl-glutamine, intravenously and perioperatively given, on postoperative insulin resistance in colon cancer patients.;Secondary Objective: The secondary objectives of the research protocol are focused on the possible mechanisms of action of: - The effect of the dipeptide alanyl-glutamine on intracellular signalling in muscle tissue. - The effect of the dipeptide alanyl-glutamine on glutathione concentration in muscle tissue. - The effect of the dipeptide alanyl-glutamine on the amino acid concentration in muscle tissue. - The effect of the dipeptide alanyl-glutamine on the inflammatory response in the circulating compartment. - The effect of the dipeptide alanyl-glutamine on antioxidant/oxidant parameters in the circulating compartment. ;Primary end point(s): Insulin resistance	—

Measure

Time frame

Main Objective: The effect of the dipeptide alanyl-glutamine, intravenously and perioperatively given, on postoperative insulin resistance in colon cancer patients.;Secondary Objective: The secondary objectives of the research protocol are focused on the possible mechanisms of action of: - The effect of the dipeptide alanyl-glutamine on intracellular signalling in muscle tissue. - The effect of the dipeptide alanyl-glutamine on glutathione concentration in muscle tissue. - The effect of the dipeptide alanyl-glutamine on the amino acid concentration in muscle tissue. - The effect of the dipeptide alanyl-glutamine on the inflammatory response in the circulating compartment. - The effect of the dipeptide alanyl-glutamine on antioxidant/oxidant parameters in the circulating compartment. ;Primary end point(s): Insulin resistance

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026